Galectin Therapeutics Inc Stock Price, News & Analysis

Galectin Therapeutics (NASDAQ: GALT), a leader in developing galectin protein-targeting therapeutics, has announced its participation in the upcoming H.C. Wainwright MASH Investor Conference on October 7, 2024. Joel Lewis, CEO, and Dr. Khurram Jamil, CMO, will be attending the event.

Dr. Jamil is scheduled to present at 10:00 AM ET on October 7, 2024, providing the latest updates on the company's clinical programs and pipeline advancements. Interested parties can access the presentation webcast through a provided link or via the Events & Presentation page in the investors section of the Galectin Therapeutics website.

This conference participation underscores Galectin Therapeutics' commitment to keeping investors informed about their progress in developing innovative therapeutics targeting galectin proteins.

Galectin Therapeutics (NASDAQ: GALT), a leader in galectin protein-targeted therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 in New York, NY.

Key highlights:

• Joel Lewis, CEO, and Dr. Khurram Jamil, CMO, will attend the conference
• Dr. Jamil will deliver a company presentation on September 9, 2024, at 12:00 PM ET
• The presentation will be accessible via webcast on the company's website
• Galectin's management team will be available for one-on-one meetings with interested investors

This conference provides Galectin Therapeutics an opportunity to showcase its progress and engage with potential investors in the biotechnology sector.

Galectin Therapeutics (NASDAQ: GALT) reported financial results for Q2 2024 and provided a business update. Key highlights include:

1. The NAVIGATE Phase 2b/3 trial of belapectin for MASH cirrhosis is on track for interim top-line analysis in December 2024.

2. Presented data at EASL 2024 showing no correlation between collagen content in liver biopsies and portal pressure in MASH cirrhotic patients.

3. As of June 30, 2024, the company had $25.6 million in cash and cash equivalents, with an additional $10 million available under a line of credit.

4. Q2 2024 net loss was $12.4 million ($0.20 per share), compared to $9.2 million ($0.15 per share) in Q2 2023.

5. Research and development expenses increased to $9.8 million in Q2 2024 from $7.4 million in Q2 2023.

Galectin Therapeutics (NASDAQ: GALT) has appointed Dr. Khurram Jamil as Chief Medical Officer, effective immediately. Dr. Jamil, who joined the company in March 2024 as VP of Clinical Development and Medical Director, brings over 20 years of experience in hepatology and drug development. He will lead the management of the NAVIGATE clinical trial for belapectin, a potential treatment for MASH cirrhosis.

The company expects interim top-line data from the Phase 2b portion of the NAVIGATE trial in December 2024. This trial is evaluating belapectin's efficacy in preventing esophageal varices in patients with cirrhosis due to MASH. The study has randomized 357 patients across 14 countries on five continents.

Galectin Therapeutics (NASDAQ:GALT) announced its participation in the European Association for the Study of the Liver (EASL) 2024 Congress, held June 5-8 in Milan, Italy. The company will present data from its belapectin program, highlighting the lack of correlation between collagen content in liver biopsies and portal pressure in MASH cirrhotic patients. Chief Medical Officer Pol Boudes emphasized the importance of using endoscopies to detect esophageal varices caused by increased portal pressure, rather than relying on liver biopsies. The presentation, titled 'Evaluating the correlation between portal pressure, collagen proportional area, and α-smooth muscle actin in patients with portal hypertension due to MASH cirrhosis,' will be available for EASL attendees and later on Galectin's website.

Galectin Therapeutics (NASDAQ: GALT) reported its Q1 2024 financial results and provided a business update. The NAVIGATE Phase 2b/3 trial of belapectin in liver cirrhosis due to MASH continues as planned, with an interim top-line readout expected late Q4 2024 after a positive fifth DSMB meeting.

Q1 financials show $23.6M in cash with an additional $10M available from a new line of credit. R&D expenses decreased to $8.1M from $8.8M YoY, while G&A expenses increased slightly to $1.6M from $1.5M. The net loss remained constant at $11.5M or ($0.19) per share YoY.

Corporate updates include the appointment of Dr. Khurram Jamil as VP of Clinical Development. The company mourns the loss of Dr. Stephen A. Harrison, a key figure in the belapectin program.

Galectin Therapeutics Inc. (NASDAQ: GALT) will participate in the H.C. Wainwright BioConnect Conference, presenting at the fireside chat on May 20, 2024, at 4:00 PM ET at the Nasdaq World Headquarters in New York City. The management team will be available for one-on-one meetings, and a webcast link will be provided on the Company's website.